U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07885917) titled 'Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders' on Oct. 14.
Brief Summary: This is an open-label extension trial to evaluate the long-term safety and tolerability of nizubaglustat (AZ-3102) in participants with rare lysosomal disorders who have participated in a previous nizubaglustat trial and wish to continue nizubaglustat treatment.
Study Start Date: Dec. 10
Study Type: INTERVENTIONAL
Condition:
Niemann-Pick Disease Type C
GM2 Gangliosidosis
GM1 Gangliosidosis
Gaucher Disease Type 3
Intervention:
DRUG: AZ-3102
Daily oral intake of nizubaglustat (AZ-3102) dispersible tablets...